Intrinsiqq
Climb Biotherapeutics, Inc. logo

Climb Biotherapeutics, Inc. Insider Trading

CLYM

Compare
Last 12 months

Insiders bought 755K and sold $2.65M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market
−$1.9M
1 buy · 4 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
1 / 2
executives and directors
Last open-market buy
Dec 2025
Dec 12, 2025

Get an email when CLYM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 1510b5-1 plan
    Stephen Basil Thomas
    Director · sold 100,000 at $13.67
    $1.37M
    18% of stake
  • Jun 2910b5-1 plan
    Aoife Brennan
    President and CEO · sold 30,902 at $13.17
    407K
    26% of stake
  • Feb 25 – 2610b5-1 plan
    Stephen Basil Thomas
    Director · sold 50,000 at avg $7.00
    350K
    24% of stake
  • Feb 12 – 1310b5-1 plan
    Stephen Basil Thomas
    Director · sold 100,000 at avg $5.29
    529K
    33% of stake
  • Jan 5
    RA Capital Healthcare Fund LP
    Large holder · bought 7,111 at $3.50
    25K
    0.2% of stake
  • Dec 11, 2025 – Dec 12, 2025
    Peter Kolchinsky
    Director · bought 314,561 at avg $2.40
    755K
    10% of stake
  • Jun 30, 202510b5-1 plan
    Aoife Brennan
    President and CEO · sold 20,618 at $1.22
    25K
    30% of stake
  • Jun 20, 202510b5-1 plan
    Emily Pimblett
    SVP, Finance & CAO · sold 1,242 at $1.24
    2K
    6.2% of stake
  • Mar 20, 202510b5-1 plan
    Emily Pimblett
    SVP, Finance & CAO · sold 1,199 at $1.31
    2K
    7.3% of stake
  • Dec 19, 202410b5-1 plan
    Emily Pimblett
    Chief Accounting Officer · sold 1,235 at $2.02
    2K
    9.8% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CLYM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CLYM

CompareIntrinsic value
JANXJanux Therapeutics Inc.
$10.08-2.04%40
IRWDIronwood Pharmaceuticals Inc.
$4.70-0.21%63
RIGLRigel Pharmaceuticals, Inc.
$40.09-2.67%86
CAPRCapricor Therapeutics Inc.
$7.59+0.80%10
ABVCABVC BioPharma Inc.
$0.87-1.56%0
GOSSGossamer Bio Inc.
$10.72-4.54%10
CRBPCorbus Pharmaceuticals Holdings, Inc.
$2.06-15.40%10
IBIOiBio, Inc.
$0.80+0.01%10

Held by ETFs

CLYM is in 15 US ETFs. The largest of them, with CLYM's weight in each:

Spot a number that looks wrong? Check it in CLYM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CLYM

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.